Trientine tetrahydrochloride versus DPA for the management of patients with Wilson Disease: Results from the CHELATE Trial

Background and Aims Treatment of Wilson Disease (WD) with chelating agents [d-Penicillamine (DPA) or trientine] prevents the pathologic accumulation of copper. Up to now, there are no prospective controlled studies comparing DPA with trientine. The aim of the study is to determine if maintenance therapy of adults with WD using trientine tetrahydrochloride formulation (TETA4) is safe and effective compared to DPA.